Grifols, a global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. The closing of the transaction is subject to the approval…